Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target
Jaap Verweij(Deutz (Germany)), Ole S. Nielsen(Science Museums), John Radford(Manchester Academic Health Science Centre), Michelle Brown(European Organisation for Research and Treatment of Cancer), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Eugenio Donato Di Paola(European Organisation for Research and Treatment of Cancer), Ian Judson(Erasmus Hospital), A. van Oosterom(European Organisation for Research and Treatment of Cancer), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Axel Le Cesne(Institut Gustave Roussy), W. Van der Graaf(University Medical Center Groningen), Pancras C.W. Hogendoorn(Vrije Universiteit Brussel)
Cited by 403
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k